<DOC>
	<DOC>NCT00145522</DOC>
	<brief_summary>This study is to evaluate the effects of continuously combined 17b-estradiol/dydrogesterone in comparison with tibolone on the breast metabolic markers, in particular the total insulin-like growth factor-1 (IGF-1), in postmenopausal women.</brief_summary>
	<brief_title>Study to Compare the Effect of Hormone Replacement Therapy (HRT) on Breast and Cardiovascular Metabolic Markers in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Tibolone</mesh_term>
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Natural or surgical postmenopausal amenorrhea since â‰¥ 12 months, non hysterectomized women, complaining of at least 14 hot flushes per week Known, suspected or history of breast cancer or hormonedependent neoplasia, undiagnosed genital bleeding, venous or arterial history or presence of thromboembolism, cerebrovascular disease</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Menopause, IGF-1, HRT</keyword>
</DOC>